Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sofosbuvir + ribavirin + peginterferon alfa-2a in treatment-experienced adults with HCV genotype 1
2014-005388-34Phase 4Active
- Sponsor
- Azienda Ospedaliero-Universitaria di Padova
- Start
- Sep 2016
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sofosbuvir, ribavirin and interferon alfa in hepatitis C virus infection, sponsored by Azienda Ospedaliero-Universitaria di Padova. Primary endpoint: SVR12. Started Sep 2016; status: active.
02
Drugs
sofosbuvirribavirininterferon alfa
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2014-005388-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005388-34.